Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Ovarian Cancer | Research article

Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours

Authors: J. Stockley, R. Akhand, A. Kennedy, C. Nyberg, E. J. Crosbie, R. J. Edmondson

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

MCM5 is a protein involved in DNA replication, facilitating cell proliferation. In normal epithelium MCM5 expression is restricted to the cells in the basal proliferative compartments, however in the presence of a tumour MCM5 positive cells are present at the surface epithelium and are shed into bodily fluids. The aim of this study was to determine the sensitivity of MCM5 as a biomarker for the detection of endometrial and ovarian cancer.

Methods

Patients with known ovarian or endometrial cancers, or known benign gynaecological conditions, were enrolled. Informed consent was obtained prior to the collection of full void urine, and either a vaginal tampon (worn for 6–8 h), or a vaginal swab. Vaginal secretions were extracted from the tampon or swab, centrifuged and lysed. Urine samples were centrifuged and lysed. MCM5 levels were determined by MCM5-ELISA (Arquer Diagnostics Ltd).

Results

125 patients completed the study protocol, 41 patients had endometrial cancer, 26 ovarian cancer, and 58 benign controls. All patients provided a urine sample and either a tampon or vaginal swab sample. Urine MCM5 levels were higher in cancer patients than controls (p < 0.0001), there was no significant difference in levels between tampon samples or vaginal swab samples in cancer patients when compared to controls.
Performance of MCM5 to discriminate cancer from benign disease was high with an area under the ROC curve of 0.83 for endometrial cancer and 0.68 for ovarian cancer. Using a cut off of 12 pg/mL, overall sensitivity for endometrial cancer was 87.8, and 61.5% for ovarian cancer with a specificity of 75.9%.

Conclusions

MCM5 is a novel sensitive and specific biomarker for the detection of ovarian and endometrial tumours in urine samples, which is likely to have clinical utility as a diagnostic aid.
Literature
1.
go back to reference Lheureux S, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.CrossRef Lheureux S, et al. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–53.CrossRef
2.
3.
go back to reference Jacobs IJ, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.CrossRef Jacobs IJ, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian Cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.CrossRef
4.
go back to reference Kinde I, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4.CrossRef Kinde I, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4.CrossRef
5.
go back to reference Fiegl H, et al. Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomark Prev. 2004;13(5):882–8. Fiegl H, et al. Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomark Prev. 2004;13(5):882–8.
6.
go back to reference Bakkum-Gamez JN, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol. 2015;137(1):14–22.CrossRef Bakkum-Gamez JN, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol. 2015;137(1):14–22.CrossRef
7.
go back to reference Dudderidge T, et al. A novel, non-invasive test enabling bladder Cancer detection in urine sediment of patients presenting with Haematuria-a prospective multicentre performance evaluation of ADXBLADDER. Br J Cancer. 2010;103(5):701-7. Dudderidge T, et al. A novel, non-invasive test enabling bladder Cancer detection in urine sediment of patients presenting with Haematuria-a prospective multicentre performance evaluation of ADXBLADDER. Br J Cancer. 2010;103(5):701-7.
8.
go back to reference Dudderidge TJ, et al. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer. 2010;103(5):701–7.CrossRef Dudderidge TJ, et al. Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer. 2010;103(5):701–7.CrossRef
9.
go back to reference Murphy N, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005;58(5):525–34.CrossRef Murphy N, et al. p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer. J Clin Pathol. 2005;58(5):525–34.CrossRef
10.
go back to reference Snyder M, He W, Zhang JJ. The DNA replication factor MCM5 is essential for Stat1-mediated transcriptional activation. Proc Natl Acad Sci U S A. 2005;102(41):14539–44.CrossRef Snyder M, He W, Zhang JJ. The DNA replication factor MCM5 is essential for Stat1-mediated transcriptional activation. Proc Natl Acad Sci U S A. 2005;102(41):14539–44.CrossRef
11.
go back to reference Bossuyt PM, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Bmj. 2015;351:h5527.CrossRef Bossuyt PM, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Bmj. 2015;351:h5527.CrossRef
12.
go back to reference Pepe MS, et al. Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem. 2016;62(5):737–42.CrossRef Pepe MS, et al. Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem. 2016;62(5):737–42.CrossRef
15.
go back to reference Skates SJ, et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12(12):5383–94.CrossRef Skates SJ, et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12(12):5383–94.CrossRef
Metadata
Title
Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours
Authors
J. Stockley
R. Akhand
A. Kennedy
C. Nyberg
E. J. Crosbie
R. J. Edmondson
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07468-y

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine